Novartis' Kisqali Scores Big Win In Competitive CDK4/6 Space

 
• By Jessica Merrill
Breast Cancer Awareness: Microscopic image (photomicrograph) of core biopsy for infiltrating (invasive) ductal carcinoma, detected by screening mammogram. H & E stain.
Novartis' Kisqali is the first CDK4/6 inhibitor to show a survival advantage

More from ASCO

More from Conferences